A B S T R A C T
Cancer therapeutics still fall far short of our goals for treating patients with locally advanced or metastatic disease. Until recently, almost all cancer drugs were crude cytotoxic agents that discriminate poorly between cancer cells and normally dividing cells. The development of targeted biologics that recognize tumor cell surface antigens and of specific inhibitors of pathways dysregulated in cancer cells or normal cellular pathways on which a cancer cell differentially depends has provided hope for converting our increasing understanding of cellular transformation into intelligently designed anticancer therapeutics. However, new drug development is painfully slow, and the pipeline of new therapeutics is thin. The discovery of RNA interference (RNAi), a ubiquitous cellular pathway of gene regulation that is dysregulated in cancer cells, provides an exciting opportunity for relatively rapid and revolutionary approaches to cancer drug design. Small RNAs that harness the RNAi machinery may become the next new class of drugs for treating a variety of diseases. Although it has only been 9 years since RNAi was shown to work in mammalian cells, about a dozen phase I to III clinical studies have already been initiated, including four for cancer. So far there has been no unexpected toxicity and suggestions of benefit in one phase II study. However, the obstacles for RNAi-based cancer therapeutics are substantial. This article will discuss how the endogenous RNAi machinery might be harnessed for cancer therapeutics, why academic researchers and biotech and pharmaceutical companies are so excited, and what the obstacles are and how they might be overcome.
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RNA INTERFERENCE PATHWAY AND HUMAN CANCER
RNA interference (RNAi) is a conserved mechanism of post-transcriptional gene silencing in which approximately 22 small nucleotide double-stranded RNAs suppress expression of genes bearing a partially complementary sequence. 1,2 microRNAs (miRNAs) are the predominant class of endogenous small RNAs. 3 miRNAs are processed from stem-loop precursor noncoding transcripts by a series of ribonuclease enzymes into the mature double-stranded RNA. The processed miRNA is taken up in the cytoplasm by the RNA-induced silencing complex (RISC), the cellular machine for gene silencing. Only one strand (the guide or active strand) is retained in the RISC, allowing it to bind to an mRNA containing a complementary short sequence, usually in the 3Ј untranslated region. 4 The bound mRNA is inhibited from being translated into protein and is also more rapidly degraded. When the complementarity between the miRNA and the mRNA is high, the RISC ribonuclease enzyme (called argonaute or ago) can cleave the mRNA, preventing it from making protein. 5 There are about 1,000 distinct miRNAs in human cells that are estimated to regulate the expression of anywhere between 30% and 90% of human genes. 6 Each miRNA can regulate multiple genes (probably hundreds), and each gene can be regulated by different miRNAs. RNAi thereby mediates a complex combinatorial system of posttranscriptional gene regulation. 7 miRNA expression in cells varies with cell type as well as with a cell's precise stage of differentiation and function. 8 miRNA expression is perturbed in cancer cells compared with the corresponding normal tissue. 9, 10 There is increasing evidence that miRNA profiling may be the most accurate way to identify tumor cell origin 11 as well as tumor subtype, 12 prognosis, and response to therapeutic interventions. 13 Some miRNAs act as tumor suppressor genes or oncogenes.
14 Collectively these have been termed oncomirs. Some miRNAs specifically modulate important steps in cancer development, including angiogenesis 15 and metastasis. [16] [17] [18] [19] miRNAs were first linked to cancer by genetic studies in chronic lymphocytic leukemia (CLL) in which the breakpoint of a CLL translocation was found to map to the miR-15a-16-1 locus at chromosome 13q14, a region typically deleted in CLL. 20 Similarly, genetic deletion of the same locus in mice causes B-cell lymphoproliferative disorders, 21 and a germline mutation in the miR-15a-16-1 cluster was found in New Zealand black mice that spontaneously developed CLL.
22 miR-15a-16-1 acts as a tumor suppressor gene in hematopoietic cells by suppressing expression of BCL2 and likely other genes involved in apoptosis and proliferation. 23 Several other miRNAs map to fragile sites, typically rearranged in cancer, that do not encode for proteins or known tumor suppressors or oncogenes. For example, members of the let-7 family of tumor suppressor miRNAs are encoded at 3p2 (let-7g/let-7a-1), 9q22 (let-7f-1/let-7 days), 11q24 (let-7a-2), and 21q21 (let-7c) regions, which are deleted in some breast, lung, ovarian, and cervical cancers. The oncogenic miR-17ϳ92 cluster at 13q31 is amplified in various hematopoietic malignancies. miR-106b-25 maps to 7q22, which is frequently amplified in gastric cancer. 24 Recent studies suggest that multiple steps in the biogenesis of miRNAs are dysregulated in cancer. [25] [26] [27] [28] [29] Transcription factors that control coding gene expression also regulate miRNA transcription. At the same time, transcription factor genes are important miRNA targets. [30] [31] [32] [33] For example, the E2F1 transcription factor that facilitates cell cycle progression (frequently upregulated in various tumors) activates expression of the miR-17-92 and miR-106b-25 clusters, which in turn suppress E2F1 expression, establishing a negative feedback loop.
30, 34 The interplay between transcription factors and miRNAs controls the gene expression profile of a cell and determines whether it will live or die or proliferate, what it can do, and how it will respond to environmental cues.
Epigenetic changes can also affect miRNA expression. For example, miR-127 is silenced in bladder cancer cells by hypermethylation, resulting in increased levels of its target gene BCL6. 35 Other miRNAs are upregulated in ovarian cancer cells as a result of hypomethylation. 35 Alterations in miRNA processing also cause changes in miRNA expression in cancer. Levels of mature miRNAs are globally reduced in some highly malignant tumors. The miRNA processing enzymes, Drosha or Dicer, are mutated in some tumors. Impaired miRNA processing correlates with ovarian cancer progression. 36 The maturation of the let-7 family of tumor suppressors is blocked in undifferentiated tumors, such as germ cell cancers, by the LIN28 and LIN28B proteins that are not normally expressed in differentiated cells.
37 Some oncogenes also escape miRNA-mediated control in cancer by undergoing alternative splicing 38 or by deletion of part of the 3ЈUTR region containing an miRNA binding site. Loss of the let-7 recognition site, for example, is one mechanism by which the oncogene HMGA2 becomes insensitive to let-7 regulation.
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HOW THE RNAI MACHINERY CAN BE HARNESSED
The RNAi machinery, which is found in all cells, can be harnessed to knock down gene expression with a high degree of specificity. When synthetic, short double-stranded RNAs, called small interfering RNAs (siRNAs), that resemble the mature miRNA are introduced into the cytoplasm of cells, one strand is taken up by the RISC, and it can guide the cleavage of mRNAs bearing an exactly complementary sequence. 40 When the cleaved mRNA is released and degraded, another mRNA can bind and be degraded, providing a highly efficient catalytic engine for suppressing expression of one gene at a time. 41 siRNAs can be designed to knock down any gene, expanding the universe of druggable targets to the entire genome. For cancer, it will be possible to inhibit expression of not only receptor tyrosine kinases but also any antiapoptotic gene or other survival factor, tumor promoting growth factor and the key participants in their signaling pathways, or genes essential for cell proliferation, including cyclins. RNAi can be used to suppress oncogenic transcription factors-either global factors, such as Myc, or cell-type specific transcription factors-that regulate multiple key cell growth promoting pathways and are not considered viable conventional drug targets. These new types of drug targets could also, in principle, be designed to eliminate the cancer stem cells within a tumor or within other tumor cells that are relatively resistant to chemotherapy and radiation. The drug efflux systems that are one source of drug resistance are unlikely to pump out small RNA drugs. Once a target has been identified, it is only a matter of a few months to identify potent candidate siRNA drugs compared with the years that are typically required to identify a small molecule inhibitor and move from a lead compound to a highly active candidate drug. Moreover, the best siRNA sequences are active at extremely low (picomolar) concentrations, and it is generally possible to find such highly potent sequences for any gene. However, the duration of gene silencing is limited by the dilution of siRNAs that occurs with each cell division as the RISC and the siRNAs bound to it get divided between daughter cells. For proliferating tumor cells, gene silencing lasts for less than a week. However, this may be long enough to suppress key oncogenes to which cancer cells are addicted or antiapoptotic or drug resistance genes to cause irreversible tumor cell death. siRNAs could also be used to induce differentiation, cell cycle arrest, or senescence, but these changes might revert with siRNA dilution. Of course, continuous infusion or weekly dosing might be used to prolong gene silencing. Although gene targeting is highly specific for suppressing the expression of the gene bearing a complementary sequence, off-target suppression of other genes occurs through one of two mechanisms. The first involves the binding of partially complementary mRNAs, which can also be cleaved (if the complementarity is high) or their translation can be inhibited, mimicking endogenous miRNAmediated gene silencing of partially complementary target genes. 42 Generally, off-target gene suppression is much less efficient than suppression of the intended target; for most genes, off-target effects are less than two-fold. However, for some genes, even two-fold reduced gene expression can have serious consequences. Fortunately, chemical modifications of the siRNA, such as inserting a 2Ј-O-methyl ribose in the second position nucleotide of the active strand, inhibits miRNAlike off-target activity. 42 Therefore, off-target knock down of genes bearing partially complementary sequences is generally considered manageable. The other type of off-target effect is triggered by siRNA recognition as foreign by immune sensors of viral infection-either Toll-like receptors (TLR-3, TLR-7 and TLR-8) in endosomes or RIG-I in the cytoplasm-which can activate expression of type I interferons and/or pro-inflammatory cytokines, producing widespread changes in gene expression. [43] [44] [45] [46] [47] Given that the triggering of these sensors depends on siRNA sequence and concentration and can be blocked by the same chemical modifications that reduce off-target gene suppression, immunostimulation can also be controlled.
In many early studies that showed promising therapeutic effects of RNA-based drugs in animal models of disease, some (or even all) of the benefit may have been due to immunostimulatory adverse effects. 46 To anticipate toxicity and improve drug design, it is important to take immune stimulation into consideration and know the mechanism of action of any RNA-based drug. This adverse effect can, in principle, also be turned to an advantage to mobilize beneficial antitumor immune responses at the same time that a disease-causing gene is silenced. An siRNA designed both to silence the antiapoptotic gene bcl-2 and to activate RIG-I to induce interferon secretion and mobilize NK cells to the tumor more potently suppressed a mouse lung cancer than an siRNA that had only one of these activities.
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An alternative therapeutic strategy to suppressing one gene at a time using an siRNA drug is to design small nucleic acids that mimic or antagonize endogenous miRNAs. Some oncomirs act as master regulators of cell differentiation and proliferation (Table 1) . For example, exogenous expression of the let-7 miRNA family, whose primary transcripts are not processed into mature miRNAs in normal stem cells and cancer stem cells, causes stem-cell differentiation and dramatically reduces tumor cell growth and metastasis in mouse models of cancer. 49 Three other miRNAs-miR-34a, miR-24, and miR-26-which are poorly expressed in some undifferentiated cancer cells, cause cell cycle arrest.
33,50-55 These four miRNAs act as tumor suppressor genes. Three of them (let-7, miR-24, and miR-34a) also sensitize cells to DNA damage by ionizing radiation and/or chemotherapy drugs.
56-58 Their dual action as differentiating agents or suppressors of cell proliferation and DNA damage sensitizers suggests that mimicking these miRNAs might be highly effective against cancer either alone or in combination with conventional cytotoxic drugs. Given that miRNA expression is globally reduced in many cancers, restoring tumor suppressor miRNA expression in tumors that do not express them could be an attractive therapeutic strategy. 49, 53, 59, 60 Because each miRNA regulates many target genes (perhaps even hundreds), it may be more difficult for a cancer cell to develop resistance to an miRNA drug than an siRNA drug, because it would have to mutate many target gene sequences at the same time to evade the biologic effect of the miRNA.
Alternatively oncomirs that act as oncogenes could be inhibited by antisense oligonucleotide (ASO) drugs. One such oncogene is a cluster of oncogenic miRNAs (miR-17-92 and its paralogs) that promotes tumor formation at least in part by silencing the antiapoptotic gene Bim and the tumor suppressor phosphatase Pten. 61, 62 Another example is miR-155; miRNA transgenic mice constitutively expressing miR-155 in the pre-B-cell compartment rapidly develop high-grade pre-B-cell leukemias by the age of 6 months. 63 A decade of drug development of ASOs has identified nucleic acid analogs, such as locked nucleic acids (LNA), that have acceptable pharmacodynamic properties and can be administered intravenously or subcutaneously to enter cells and interfere with gene expression relatively efficiently. 64, 65 Because the delivery of siRNA and miRNA mimics into cells in vivo is still problematic and is more challenging than delivery of ASOs, some biotech companies designing miRNA-based cancer therapeutics are focusing on antagonizing oncogenic miRNAs rather than restoring tumor suppressor miRNAs. siRNA and miRNA drug development will evolve in parallel, because most of the obstacles to RNAi-based cancer therapeutics are the same for both siRNAs and miRNAs. However, siRNAs and miRNAs are two distinct entities, each with peculiar properties that could be differentially exploited to realize the full potential of RNAibased drugs. siRNAs are more specific and generally more potent gene silencing agents than miRNAs. However, they could induce drug resistance even by single-point mutations in the targeted gene sequence that need not even alter the translated protein sequence or function. However, siRNA drug cocktails might be a good way around drug resistance. Synergy will likely come by designing combinations of siRNAs that target multiple key players in one pathway or that simultaneously interfere with multiple cancer-promoting pathways. The key genes regulated by master-regulator tumor suppressor miRNAs might be good candidates for targets of either siRNA or conventional drugs. RNAi drugs are ideal for the development of personalized cancer therapies, given that a different cocktail of siRNA/miRNA drugs could be selected, depending on the genetic characteristics of a patient's tumor and its expression profile (Table 2) . However, synergy through combining multiple siRNAs into a unique formulation, although likely, has not yet been rigorously demonstrated in animals. Developing drug cocktails might also increase toxicity and would increase the complexity and cost of preclinical evaluation.
The therapeutic index of siRNA drugs could be enhanced by silencing oncogenes to which cancer cells might be addicted. For example, a recent synthetic lethality RNAi screen identified the serine/ threonine kinase STK33 as a gene required specifically for survival of KRAS-transformed cells but not untransformed cells. STK33 promotes cancer cell survival in KRAS-dependent cells by suppressing apoptosis mediated through S6K1-induced inactivation of the death agonist BAD. 66 Therefore, silencing STK33 in cancer cells might kill KRAS-transformed cancer cells with limited toxicity to normal cells. Replacing tumor suppressor miRNAs that are not expressed in cancer cells but that are uniformly expressed in differentiated normal cells might be well tolerated. However, it would be important to verify whether they affect less differentiated stem-cell compartments in which the same miRNAs are also poorly expressed. Another strategy for minimizing toxicity to normal cells is to design delivery approaches that transduce therapeutic small RNAs selectively into cancer cells relative to normal cells.
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OBSTACLES TO RNAi-BASED THERAPEUTICS
Despite the promise of RNAi for cancer therapy, some hurdles must be confronted to bring small RNAs into the clinic. 68 Small RNA drugs need to survive in extracellular fluids, which contain RNA-degrading ribonucleases, and to be taken up into the cytoplasm of cells where they can interact with the RISC in the cytoplasm. Although endocytosis via cell surface receptors might be a good first step for entry into cells, which has the potential added advantage of cell-specific targeting, a workable delivery strategy needs to release the RNA efficiently from the endosome. This step appears to be a stumbling block for many delivery approaches. The half-life of small RNAs in extracellular fluids and serum can be extended to several days without significantly affecting gene silencing activity by the same sorts of chemical modifications that reduce off-target effects and by changing the nucleotide linkages at the ends to phosphorothioates that are resistant to exonuclease cleavage. In addition, naked small RNAs are rapidly excreted by the kidney; therefore, they need to be modified or complexed into a larger particle to circumvent rapid elimination via glomerular filtration. 69 Small RNAs do not get across the cell's plasma membrane and are not taken up even by cells, like microphages, that are constantly sampling their environment. The major obstacle to RNAi-based therapeutics is intracellular delivery. This is especially true for cancer therapy, given that delivery is more problematic for cells disseminated throughout the body, as is the case for most cancers that are not cured by surgery. Several hundred biotechnology and pharmaceutical companies are working to solve the small RNA delivery problem. This indicates that the problem is real, that none of the current solutions is ideal, and that the payoff for enabling small RNA delivery could be enormous. Multiple delivery strategies are being examined, as has been reviewed elsewhere.
68,70 These include chemically conjugating the RNA to small molecules, such as cholesterol, glycans, or folate that bind to cell surface receptors, some of which may be more heavily expressed on cancer versus normal cells; incorporating small RNAs within nanoparticles or liposomes, which may also be modified for cell-specific targeting; binding the small RNAs to peptides that facilitate cell membrane penetration, either nonspecifically or via binding to cell-specific receptors; and fusing the small RNAs to structured pieces of RNA, called aptamers, that recognize cell surface-receptors. It is likely that different solutions will be used to transfect RNA into different types of tumors in different locations. Cholesterolconjugated siRNAs, LNA ASOs and miRNA inhibitors (antagomiRs), and liposome-encapsulated RNAs have already been shown to induce gene silencing in a variety of tissues when administered systemically in mice and nonhuman primates. 65, 71, 72 Two types of tissues are more amenable to targeting: the liver (and possibly some other heavily vascularized central organs that trap injected particles and liposomes) and directly accessible mucosal surfaces or body cavities. RNA-containing particles might also selectively target cancer tissues given that the tumor vasculature is typically disorganized and permeable to particles as large as 200 nm, whereas normal endothelium in most organs does not allow passage of molecules larger than 5 nm. Cholesterol-conjugated siRNAs might be useful for topical applications-for example, to prevent malignant transformation of genetically or environmentally caused dysplastic conditions that are localized to the mucosae because they are efficiently taken up and cause gene silencing at least in some mucosal epithelia. 73, 74 Examples of this include head and neck dysplastic lesions secondary to alcohol and tobacco use or the cancers that arise from them, which typically spread locally, and dysplasias in the genital or oral cavity caused by oncogenic human papilloma virus serotypes. Although the skin might also appear to be a good site (ie, for melanoma), the cornified outer layer impedes RNA delivery and needs to be disrupted to transfect this highly accessible epithelium. Cholesterol-conjugation also enhances the systemic half-life of intravenously injected small RNAs, because cholesterol-conjugated RNAs bind to LDL particles, enhancing their intravascular half-life. 75 Currently available liposomes can target the liver efficiently 72 and may be useful for treating primary hepatocellular carcinoma as well as GI malignancies whose major site of metastatic spread is the liver. However, liposome formulations able to deliver RNAs contain cationic lipids, are complicated to manufacture, and may have nonnegligible hepatotoxicity.
Solving the delivery problem could be more important for oncology applications than for treatment of other types of disease, given that tumor elimination will require efficient gene silencing in virtually all Harnessing RNAi for cancer drug development and treatment. Tumor cell lines with defined genetic characteristics can be used to perform genome-wide RNAi-based screening to identify genes/pathways involved in key neoplastic processes, such as uncontrolled proliferation, evasion from apoptosis, self-renewal/ differentiation, or drug resistance. The identified genes can be targets for developing conventional small molecule drugs or small RNA drugs. Identification of the particular genetic alterations and changes in mRNA and miRNA expression in a tumor can be used to identify the tumor subtype and guide prognosis. In the near future, evaluating miRNA expression signatures may prove superior to pathologic diagnosis for tumor subtyping. Molecular subtyping can be used to stratify patients for clinical trials and to design tailored cancer therapy. cells. However, RNAi-based therapeutics may be able to cause differentiation or death of the highly malignant subpopulation of tumor-initiating cells that may be responsible for tumor resistance, relapse, and possibly metastasis and are often resistant to conventional cytotoxic therapies. Indeed, it is likely that combining RNAi-based therapeutics and conventional drugs will be more effective than either alone, because they will be able to complement the weak points of each other. It is premature to predict which of the delivery methods that have been described so far, or that are in development, will provide practical solutions to deliver siRNAs/miRNAs efficiently to metastatic tumors. More than one delivery approach may work, and some may be better suited for one type or location of cancer than another. Cancer cellspecific targeted delivery will reduce not only the dose but also the toxicity to normal cells.
EARLY RNAI-BASED CLINICAL STUDIES: WHERE WE STAND
Four RNAi-based drugs to treat cancer are already being evaluated in early-stage clinical trials ( Table 3 ). The good news is that, so far, there has been no significant dose-limiting or unexpected toxicity in about a dozen early-stage clinical studies to evaluate small RNA-based therapies for cancer and other indications. The first RNAi-based drug study was initiated by Calando Pharmaceuticals, which manufactures siRNA-containing nanoparticles. These particles are made of a cyclodextrin-containing polymer (CDP) that binds siRNA by charge interactions and is complexed with another small molecule that is used to bind polyethylene glycol (PEG) to prevent particle aggregation and rapid uptake by reticuloendothelial cells and with transferrin to enhance cell uptake, given that transferrin receptors are ubiquitously expressed on cells. 76, 77 The particles are endocytosed and the CDP induces osmotic swelling of the endosome, causing it to burst and release the RNA into the cytosol. PEGylated-transferrin CDPs have been used to deliver siRNAs against the ribonucleotide reductase subunit 2 intravenously to treat subcutaneous mouse hepatoma, human melanoma tumors, and disseminated human Ewing's sarcoma cancers in immunosuppressed mice, showing an antitumor effect at doses of 2.5 to 10 mg/kg. When administered systemically in nonhuman primates, no liver toxicity or immune response was observed at doses up to 9 mg/kg siRNA, although the antitumor efficacy was not assessed in this model. PEGylated CDPs that contain ribonucleotide reductase subunit 2 siRNAs are currently being evaluated using multiple intravenous injections over two cycles in a phase I dose-escalation study in patients with refractory solid tumors. An early report shows nanoparticle uptake and gene silencing in human melanomas in three patients, but no antitumor effects in the biopsied tissues were reported, and no clinical effects have yet been reported.
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LNA (stabilized ASOs) 79 designed to knock down hypoxia-induced factor 1 (HIF-1␣) and the antiapoptotic protein survivin are being evaluated in two dose-escalation phase I studies in a collaboration between Santaris Pharma and Enzon Pharmaceuticals in patients with advanced solid tumors or lymphoma. Preliminary data suggest no dose-limiting toxicity and the possibility of disease stabilization in two sarcoma patients.
Stable nucleic acid-lipid particles (SNALPs), a form of liposome, have been used to deliver siRNAs to suppress ApoB expression in the liver of both mouse and nonhuman primates, leading to impressive decreases in blood cholesterol levels. 72 The same SNALPs loaded with an antihepatitisBvirussiRNAinhibitedhepatitisBvirusreplicationinmice. 80 Aphase I dose-escalation study is now being conducted by Alnylam Pharmaceuticals to establish the safety profile of SNALPs loaded with siRNAs targeting the kinesin spindle protein and vascular endothelial growth factor in patients with primary hepatocellular cancer or liver metastases.
RNAi-based drug development is still in its infancy but developing rapidly. In the next few years, the results from the first studies will become available, and other studies are likely to begin soon. Although the path forward will likely not be completely smooth, we are cautiously optimistic that this new technology will provide powerful weapons to attack cancer (Fig 1) . 
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Glossary Terms
Antagomir: Antagomirs are cholesterol-conjugated oligonucleotides used to antagonize endogenous microRNAs.
Antisense oligonucleotides: Short strands of chemically modified DNA or DNA-RNA hybrids designed to regulate gene expression by binding through Watson-Crick base hybridization to a specific mRNA "sense" sequence. This results in blocking translation of the specific mRNA and, consequently, blocking the expression of a specific protein.
Aptamer: A single-stranded DNA sequence that may vary in length from 25 nucleotides to 100 nucleotides, DNA aptamers can be formulated to bind to oligosaccharides, peptides, and proteins. They thus function as decoy molecules that may be agonists, antagonists, or enzyme inhibitors.
Cyclodextrins: Cyclodextrins (sometimes called cycloamyloses) are a family of compounds made up of sugar molecules bound together in a ring (cyclic oligosaccharides).
Epigenetic:
The transfer of information from one cell to its descendants without the information's being encoded in the nucleotide sequence of the DNA. The methylation of the promoter to inactivate a gene is an example of an epigenetic change. Epigenetic inheritance is typically transmitted in dividing cells. Although rare, it is occasionally seen in traits being transmitted from one generation to another. Epigenetic variants can arise spontaneously and just as spontaneously revert.
Glycan:
The term glycan refers to a polysaccharide or oligosaccharide.
Glycan may also be used to refer to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan. Glycans usually consist solely of O-glycosidic linkages of monosaccharides. Glycans can be homo or heteropolymers of monosaccharide residues, and can be linear or branched.
Locked nucleic acid:
A locked nucleic acid (LNA), often referred to as inaccessible RNA, is a modified RNA nucleotide. The ribose moiety of an LNA nucleotide is modified with an extra bridge connecting the 2Ј oxygen and 4Ј carbon. The bridge "locks" the ribose in the 3Ј-endo (North) conformation, which is often found in the A-form of DNA or RNA. LNA nucleotides can be mixed with DNA or RNA bases in the oligonucleotide. The locked ribose conformation enhances base stacking and backbone pre-organization. This significantly increases the thermal stability (melting temperature) of oligonucleotides. 
MicroRNAs: Endogenous noncoding
SNALP:
Stable nucleic acid lipid particles (SNALPs) are microscopic particles approximately 120 nanometers in diameter. They have been used to deliver siRNAs therapeutically to mammals in vivo. In SNALPs the siRNA is surrounded by a lipid bilayer containing a mixture of cationic and fusogenic lipids, coated with diffusible polyethylene glycol.
